Novavax (XBUL:NVV1) Current Deferred Revenue : лв1,142 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Novavax Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Novavax's current deferred revenue for the quarter that ended in Sep. 2024 was лв1,142 Mil.

Novavax Current Deferred Revenue Historical Data

The historical data trend for Novavax's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Current Deferred Revenue Chart

Novavax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Current Deferred Revenue

Get a 7-Day Free Trial

3.12

508.57

2,648.58

688.95

449.16

Novavax Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Current Deferred Revenue	Get a 7-Day Free Trial															357.73	449.16	448.40	1,240.38	1,141.78

Novavax Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Novavax's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (XBUL:NVV1) » Definitions » Current Deferred Revenue

Comparable Companies

Traded in Other Exchanges

NVAX:USA NVAX:Mexico NVV1:Germany NVV1:Germany NVV1:Germany NVAX:Austria

Address

700 Quince Orchard Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Novavax Headlines

No Headlines